ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
PDZK1-ULK1 Axis Triggers Lipophagy to Inhibit Tumor Progression and Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Drugging small-molecule compounds in autophagy-dependent cell death to overcome cancer therapy resistance.Apoptosis : an international journal on programmed cell death · 2026Review
- Targeting STAT3-mediated lipid metabolism reprogramming overcomes chemoresistance in acute myeloid leukemia.Cell death & disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Clear cell renal cell carcinoma (ccRCC) is characterized by aberrant lipid droplet (LD) accumulation, which promotes tumor progression and sunitinib resistance. However, the underlying molecular mechanisms remain incompletely understood. This study shows that reduced PDZK1 expression correlates with LD accumulation and poor prognosis in ccRCC patients. Single-cell RNA sequencing indicates that downregulated PDZK1 expression associates with impaired LD degradation in ccRCC cells. Functional studies demonstrate that PDZK1 inhibits LD accumulation by upregulating ULK1 expression and activating lipophagy, indicating the PDZK1-ULK1 axis as a therapeutic target to enhance sunitinib efficacy. Mechanistically, CUT&Tag analysis reveals that LEF1 directly binds to the ULK1 promoter. PDZK1 interacts with LEF1 via its C-terminus, sequestering LEF1 in the cytoplasm, thereby enhancing ULK1 transcription and autophagy activity. Pharmacological ULK1 activation with LYN-1604 restores sunitinib sensitivity in PDZK1-knockdown cells and synergizes with sunitinib in xenograft models, reducing tumor growth and LD accumulation. Clinical data demonstrate a strong correlation between ULK1 expression levels in tumor tissues and sunitinib response (AUC = 0.9063), suggesting its potential as a predictive biomarker. Collectively, the PDZK1-ULK1 axis regulates LD homeostasis in ccRCC. Targeting this axis via ULK1 activation represents a novel strategy to overcome sunitinib resistance, with ULK1 as a potential biomarker for sunitinib efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.